Terpenoid ID | TKC030239 | |
Chirality | TKC103494 | |
Cell line | 0 | |
Protein target | 28 | |
DiseaseNCIT | 0 | |
ORDO | 0 | |
ICD | 126 |
ID | Cell Line | Synonyms | Value | Unit | Type | NCIt | ORDO |
---|---|---|---|---|---|---|---|
TKC030239 | HepG2 | 25119.0 | nM | Potency | C3728 | Orphanet_449 | |
TKC030239 | mast cells | 5.0 | 10'-5M | ID50 | |||
TKC030239 | RAW264.7 | RAW264 | 61.0 | nM | IC50 | C21604 | |
TKC030239 | HepG2 | 2512.0 | nM | Potency | C3728 | Orphanet_449 | |
TKC030239 | MDA-N | MDAN | 100000.0 | nM | GI50 | C3802 | |
TKC030239 | NCI-H23 | NCI.H23; NCI H23; H-23; H23; NCIH23 | 100000.0 | nM | GI50 | C3512 | |
TKC030239 | SN12C | SN-12C | 31769.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC030239 | ACHN | 100000.0 | nM | GI50 | C6975 | Orphanet_319298 | |
TKC030239 | UO-31 | UO.31; UO31; U031 | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC030239 | HL-60 | HL 60; HL.60 HL60; Human Leukemia-60 | 100000.0 | nM | GI50 | C9154 | Orphanet_519 |
TKC030239 | HOP-92 | HOP 92; HOP.92; HOP92; Hop92; Hopkins-92 | 100000.0 | nM | GI50 | C2926 | |
TKC030239 | DU-145 | DU-145; Du-145; DU 145; DU_145; DU.145; Duke University 145 | 100000.0 | nM | GI50 | C4863 | |
TKC030239 | SF-539 | SF-539; SF-539 BT; SF.539; SF 539 | 100000.0 | nM | GI50 | C3796 | Orphanet_251576 |
TKC030239 | Malme-3M | MALME-3M; MALME 3M; Malme-3 M; MALME.3M; Malme3M; MALME3M; Malme-3 Monolayer | 100000.0 | nM | GI50 | C3224 | |
TKC030239 | SK-MEL-5 | SK-Mel-5; SK MEL 5; SK.MEL.5; SK-MEL5; SKMel-5; SKMEL-5; SKMEL5; SKMel5; SKmel5; AA-Mel | 100000.0 | nM | GI50 | C3510 | |
TKC030239 | K562 | K562; K.562; K 562; KO; GM05372; GM05372E | 100000.0 | nM | GI50 | C9110 | Orphanet_521 |
TKC030239 | A498 | A498 | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC030239 | OVCAR-3 | Ovcar-3; OVCAR 3; OVCAR.3; NIH:OVCAR-3; NIH:Ovcar-3; NIH:OVCAR3; NIH-OVCAR-3; NIHOVCAR3; OVCAR3; Ovcar3 | 100000.0 | nM | GI50 | C105555 | |
TKC030239 | HOP-62 | HOP 62; Hop 62; HOP.62; HOP62; Hop62; Hopkins-62 | 100000.0 | nM | GI50 | C3512 | |
TKC030239 | MOLT-4 | Molt-4; MOLT 4; Molt 4; MOLT.4; MOLT4; Molt4; GM02219; GM02219C; GM2219C; GM02219D | 100000.0 | nM | GI50 | C9142 | Orphanet_99861 |
TKC030239 | NCI/ADR-RES | NCI/ADR-RES; NCI.ADR.RES; NCIADR.RES; NCI/ADRRES; NCIADRRES; ADR-RES; MCF-7/ADR; MCF-7/ADR-RES; MCF-7/AdrR; MCF-7/Adr; MCF-7/adr; MCF-7ADR; MCF7-ADR; MCF7ADR; OVCAR-8/ADR; OVCAR8/ADR | 100000.0 | nM | GI50 | C105555 | |
TKC030239 | U-251 | U-251 MG; U-251-MG; U-251_MG; U251-MG; U251MG; U-251; U251; U251n; U251N; 251 MG; 251MG; 251 MG(6) | 100000.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC030239 | OVCAR-8 | OVCAR 8; NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 | 100000.0 | nM | GI50 | C105555 | |
TKC030239 | OVCAR-5 | OVCAR 5; NIH:OVCAR-5; OVCAR.5; OVCAR5; Ovcar5; OVCA5 | 100000.0 | nM | GI50 | C105555 | |
TKC030239 | SNB-19 | SNB.19; SNB19; Surgical Neurology Branch-19 | 100000.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC030239 | SR | SR-786; SR786 | 100000.0 | nM | GI50 | C37193 | Orphanet_300895 |
TKC030239 | MDA-MB-231 | MDA_MB_231; MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA-231P; MDA231; MDA231-BRE; MB231; MD Anderson-Metastatic Breast-231 | 8.0 | % | Activity | C5214 | |
TKC030239 | TK-10 | TK.10; TK 10; TK10 | 100000.0 | nM | GI50 | C4033 | Orphanet_319276 |
TKC030239 | SW-620 | SW-620; SW 620; SW.620 | 100000.0 | nM | GI50 | C4349 | |
TKC030239 | NCI-H522 | NCI.H522; H522; H-522; NCI-522; NCI522; NCIH522 | 100000.0 | nM | GI50 | C3512 | |
TKC030239 | M14 | M14-MEL; UCLA-SO-M14; UCLA SO M14; UCLA-SO-14; UCLASO-M14; Melanoma 14; M-14 | 100000.0 | nM | GI50 | C3802 | |
TKC030239 | KM12 | KM-12; KM.12 | 100000.0 | nM | GI50 | C4910 | |
TKC030239 | NCI-H322M | NCI.H322M; H322M; H-322M; H-322m | 100000.0 | nM | GI50 | C2923 | |
TKC030239 | OVCAR-4 | OVCAR 4; NIH:OVCAR-4; NIH:OVCAR4; OVCAR.4; OVCAR4; Ovcar4 | 100000.0 | nM | GI50 | C105555 | |
TKC030239 | RPMI-8226 | RPMI 8226; RPMI.8226; RPMI8226; RPMI no. 8226; RPMI no 8226; RPMI #8226; 8226; RPMI 8226/S; RPMI-8226S; RPMI8226/S; 8226/S; Roswell Park Memorial Institute 8226; GM02132; GM2132; GM 2132; GM02132C; Simpson | 340.0 | nM | GI50 | C3242 | Orphanet_29073 |
TKC030239 | LOX IMVI | LOX/IMVI; LOX IMVI; LOXIM-VI; LOXIMVI; LOX | 100000.0 | nM | GI50 | C3802 | |
TKC030239 | BT-549 | BT 549; BT.549; BT549 | 100000.0 | nM | GI50 | C4194 | |
TKC030239 | SK-MEL-2 | SK-Mel-2; SK-Mel 2; SK-mel-2; SK-MEL2; SK.MEL.2; SK Mel 2; SK MEL 2; SKMEL-2; SKMEL2; SKmel2; SK-ML2; SKml2 | 100000.0 | nM | GI50 | C3224 | |
TKC030239 | A549 | 7.0 | % | Activity | C3512 | ||
TKC030239 | SNB-75 | SNB.75; SNB75; Surgical Neurology Branch-75 | 100000.0 | nM | GI50 | C3058 | Orphanet_360 |
TKC030239 | HCC 2998 | HCC-2998; HCC.2998; HCC 2998; Hamon Cancer Center 2998 | 100000.0 | nM | GI50 | C4349 | |
TKC030239 | HCT-15 | HCT-15; HCT.15; HCT15 | 100000.0 | nM | GI50 | C4349 | |
TKC030239 | HCT-116 | HCT-116; HCT.116; HCT_116; HCT116; HCT116wt; CoCL2 | 100000.0 | nM | GI50 | C4910 | |
TKC030239 | SF-268 | SF-268; SF.268; SF 268 | 100000.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC030239 | MCF7 | 20000.0 | nM | IC50 | C4194 | ||
TKC030239 | EKVX | 82414.0 | nM | GI50 | C3512 | ||
TKC030239 | PC-3 | PC3; PC.3 | 100000.0 | nM | GI50 | C4863 | |
TKC030239 | SK-OV-3 | SKOV-3; SK-OV3; SK.OV.3; SKOV3; Skov3; SKO3 | 100000.0 | nM | GI50 | C7978 | |
TKC030239 | T47D | 100000.0 | nM | GI50 | C4194 | ||
TKC030239 | UACC-62 | UACC 62; UACC.62; UACC62; University of Arizona Cell Culture-62 | 100000.0 | nM | GI50 | C3224 | |
TKC030239 | NCI-H460 | NCI.H460; H460; H-460; NCIH460; NCI-HUT-460; NCI-460 | 100000.0 | nM | GI50 | C4450 | |
TKC030239 | CAKI-1 | CAL 1; Centre Antoine Lacassagne-1 | 100000.0 | nM | GI50 | C3224 | |
TKC030239 | MDA-MB-435 | MDA-MB435; MDAMB435; MDA.MB.435; MDA-435; MDA 435; MDA435; MD Anderson-Metastatic Breast-435 | 100000.0 | nM | GI50 | C3802 | |
TKC030239 | SF-295 | SF-295; SF.295; SF 295 | 100000.0 | nM | GI50 | C3058 | Orphanet_360 |
TKC030239 | IGROV-1 | Igrov-1; IGROV 1; IGR-OV1; IGROV1; Igrov1; IGR.OV1; IGROV; OV1/P; OV1/p; OV1-P | 100000.0 | nM | GI50 | C7979 | Orphanet_454723 |
TKC030239 | Hs-578T | HS 578T; Hs-578T; HS-578T; Hs_578t; Hs-578-T; HS-578-T; Hs 578.T; HS578T; Hs578T; Hs578t; HS0578T; 578T; HS578; Hs578; Homo sapiens No. 578, tumor cells | 100000.0 | nM | GI50 | C4194 | |
TKC030239 | 786-0 | 786-o; 786O; 786-0; 786.O; 786-O RCC; RCC 786-O; RCC_7860; RCC 7860; 7860; 786-0WT | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC030239 | UACC-257 | UACC 257; UACC.257; UACC257; University of Arizona Cell Culture-257 | 100000.0 | nM | GI50 | C3224 | |
TKC030239 | CCRF-CEM | CCRF/CEM; CCRFCEM; CCRF.CEM; CCRF CEM; CCRF; CEM; CEM-CCRF; CEM-CCRF (CAMR); CCRF/CEM/0; CEM/0; CEM-0; CCRF-CEM/S; GM03671; GM03671C | 18707.0 | nM | GI50 | C7953 | Orphanet_99861 |
TKC030239 | NCI-H226 | NCI.H226; NCI H226; H226; H-226; HUT-226; HUT 226; NCIH226 | 100000.0 | nM | GI50 | C45662 | Orphanet_50251 |
TKC030239 | HT-29 | HT 29; HT29 | 100000.0 | nM | GI50 | C4349 | |
TKC030239 | SK-MEL-28 | SK-Mel-28; SK.MEL.28; SK-MEL 28; SK MEL-28; SK MEL 28; SK Mel 28; SKMel-28; SKMEL-28; SK-MEL28; SK-Mel28; SK Mel28; SKMEL28; SKMel28; SKmel28; SKML-28; SK28; AU-Mel; P-36; P36 | 100000.0 | nM | GI50 | C3510 | |
TKC030239 | RXF 393 | RXF393L; RXF-393 L; RXF-393; RXF 393; RXF.393; RXF393; RXF 393NL | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC030239 | COLO 205 | Colo 205; CoLo 205; COLO-205; Colo-205; COLO.205; Colo205; COLO205; Co 205; Colorado 205 | 100000.0 | nM | GI50 | C4349 | |
TKC030239 | B16-F10 | B16/F10; B16 F10; B16F10; B16 melanoma F10 | 1.0 | % | Activity | C21790 |
ID | Uniport | Pref_name | Gene name | value | unit | type |
---|---|---|---|---|---|---|
TKC030239 | P10636 | Microtubule-associated protein tau | MAPT | 4467 | nM | Potency |
TKC030239 | P11473 | Vitamin D3 receptor | VDR | 44668 | nM | Potency |
TKC030239 | Q16637 | Survival motor neuron protein | SMN1,SMN2 | 794 | nM | Potency |
TKC030239 | Q16637 | Survival motor neuron protein | SMN1,SMN2 | 794 | nM | Potency |
TKC030239 | Q9NUW8 | Tyrosyl-DNA phosphodiesterase 1 | TDP1 | 25929 | nM | Potency |
TKC030239 | P08684 | Cytochrome P450 3A4 | CYP3A4 | >19953 | nM | Potency |
TKC030239 | P08684 | Cytochrome P450 3A4 | CYP3A4 | >50000 | nM | IC50 |
TKC030239 | P10275 | Androgen receptor | AR | 14 | nM | Potency |
TKC030239 | P15207 | Androgen receptor | Ar | <181970 | nM | IC50 |
TKC030239 | Q9NPD5 | Solute carrier organic anion transporter family member 1B3 | SLCO1B3 | 114 | % | Inhibition |
TKC030239 | Q9Y6L6 | Solute carrier organic anion transporter family member 1B1 | SLCO1B1 | 98 | % | Inhibition |
TKC030239 | Q16236 | Nuclear factor erythroid 2-related factor 2 | NFE2L2 | 92 | nM | Potency |
TKC030239 | P19838 | Nuclear factor NF-kappa-B p105 subunit | NFKB1 | 14 | nM | Potency |
TKC030239 | P08183 | ATP-dependent translocase ABCB1 | ABCB1 | 50000 | nM | IC50 |
TKC030239 | O75496 | Geminin | GMNN | 20596 | nM | Potency |
TKC030239 | P04150 | Glucocorticoid receptor | NR3C1 | 30 | nM | Ki |
TKC030239 | P04150 | Glucocorticoid receptor | NR3C1 | 69 | % | Inhibition |
TKC030239 | P83916 | Chromobox protein homolog 1 | CBX1 | 79433 | nM | Potency |
TKC030239 | Q96QE3 | ATPase family AAA domain-containing protein 5 | ATAD5 | 65 | nM | Potency |
TKC030239 | P25779 | Cruzipain | 39811 | nM | Potency | |
TKC030239 | Q99714 | 3-hydroxyacyl-CoA dehydrogenase type-2 | HSD17B10 | 31623 | nM | Potency |
TKC030239 | Q03164 | Histone-lysine N-methyltransferase 2A | KMT2A | 8913 | nM | Potency |
TKC030239 | Q16665 | Hypoxia-inducible factor 1-alpha | HIF1A | 200 | nM | Potency |
TKC030239 | P19793 | Retinoic acid receptor RXR-alpha | RXRA | 50119 | nM | Potency |
TKC030239 | P08482 | Muscarinic acetylcholine receptor M1 | Chrm1 | 251 | nM | Potency |
TKC030239 | O95342 | Bile salt export pump | ABCB11 | 251700 | nM | IC50 |
TKC030239 | Q92887 | ATP-binding cassette sub-family C member 2 | ABCC2 | 124 | % | Activity |
TKC030239 | Q9R1A7 | Nuclear receptor subfamily 1 group I member 2 | Nr1i2 | 19953 | nM | Potency |
TKC030239 | P08235 | Mineralocorticoid receptor | NR3C2 | 2.9 | nM | EC50 |
TKC030239 | P08235 | Mineralocorticoid receptor | NR3C2 | 0.5 | nM | Kd |
TKC030239 | P54855 | UDP-glucuronosyltransferase 2B15 | UGT2B15 | 0 | pm/min/mg | Activity |
TKC030239 | P11308 | Transcriptional regulator ERG | ERG | 11220 | nM | Potency |
TKC030239 | P62826 | GTP-binding nuclear protein Ran | RAN | 2060 | nM | Potency |
TKC030239 | P16662 | UDP-glucuronosyltransferase 2B7 | UGT2B7 | 0 | pm/min/mg | Activity |
TKC030239 | Q27757 | Luciferin 4-monooxygenase | >52000 | nM | AC50 | |
TKC030239 | O35627 | Nuclear receptor subfamily 1 group I member 3 | Nr1i3 | 68 | % | Remaining activity |
TKC030239 | P04278 | Sex hormone-binding globulin | SHBG | 631 | nM | Kd |
TKC030239 | P06537 | Glucocorticoid receptor | Nr3c1 | 43 | nM | Kd |
TKC030239 | P21447 | ATP-dependent translocase ABCB1 | Abcb1a | >50000 | nM | IC50 |
TKC030239 | P21447 | ATP-dependent translocase ABCB1 | Abcb1a | >50000 | nM | IC50 |
TKC030239 | P08185 | Corticosteroid-binding globulin | SERPINA6 | 13 | nM | Ki |
TKC030239 | P46720 | Solute carrier organic anion transporter family member 1A1 | Slco1a1 | 13000 | nM | Km |
TKC030239 | P51589 | Cytochrome P450 2J2 | CYP2J2 | >50000 | nM | IC50 |
TKC030239 | P56937 | 3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7 | HSD17B7 | 10 | % | Inhibition |
TKC030239 | Q9UNQ0 | Broad substrate specificity ATP-binding cassette transporter ABCG2 | ABCG2 | 70 | % | Activity |
TKC030239 | Q9NRY4 | Rho GTPase-activating protein 35 | ARHGAP35 | 41.6 | nM | EC50 |
Uniport ID | Uniport Name | ICD-11 |
---|---|---|
P10636 | TAU_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 | TAU_HUMAN | Alzheimer disease [ICD-11: 8A20] |
P10636 | TAU_HUMAN | Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 | TAU_HUMAN | Choreiform disorder [ICD-11: 8A01] |
P10636 | TAU_HUMAN | Parkinsonism [ICD-11: 8A00] |
P10636 | TAU_HUMAN | Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 | TAU_HUMAN | Neurodegenerative disorder [ICD-11: 8A20-8A23] |
P11473 | VDR_HUMAN | Chronic kidney disease [ICD-11: GB61] |
P11473 | VDR_HUMAN | Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 | VDR_HUMAN | Hyper-parathyroidism [ICD-11: 5A51] |
P11473 | VDR_HUMAN | Hypo-parathyroidism [ICD-11: 5A50] |
P11473 | VDR_HUMAN | Mineral deficiency [ICD-11: 5B5K] |
P11473 | VDR_HUMAN | Psoriasis [ICD-11: EA90] |
P11473 | VDR_HUMAN | Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 | VDR_HUMAN | Low bone mass disorder [ICD-11: FB83] |
P11473 | VDR_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 | VDR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P11473 | VDR_HUMAN | Prostate disease [ICD-11: GA91] |
P11473 | VDR_HUMAN | Abnormal micturition [ICD-11: MF50] |
P11473 | VDR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 | VDR_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 | VDR_HUMAN | Acne vulgaris [ICD-11: ED80] |
Q16637 | SMN_HUMAN | Muscular atrophy [ICD-11: 8B61] |
Q16637 | SMN_HUMAN | Muscular atrophy [ICD-11: 8B61] |
Q16637 | SMN_HUMAN | Muscular atrophy [ICD-11: 8B61] |
Q16637 | SMN_HUMAN | Muscular atrophy [ICD-11: 8B61] |
P08684 | CP3A4_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08684 | CP3A4_HUMAN | Atopic eczema [ICD-11: EA80] |
P08684 | CP3A4_HUMAN | Anxiety disorder [ICD-11: 6B00-6B0Z] |
P08684 | CP3A4_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08684 | CP3A4_HUMAN | Atopic eczema [ICD-11: EA80] |
P08684 | CP3A4_HUMAN | Anxiety disorder [ICD-11: 6B00-6B0Z] |
P10275 | ANDR_HUMAN | Acne vulgaris [ICD-11: ED80] |
P10275 | ANDR_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P10275 | ANDR_HUMAN | Alcoholic liver disease [ICD-11: DB94] |
P10275 | ANDR_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
P10275 | ANDR_HUMAN | Cardiovascular disease [ICD-11: BA00-BE2Z] |
P10275 | ANDR_HUMAN | Chronic obstructive pulmonary disease [ICD-11: CA22] |
P10275 | ANDR_HUMAN | Female pelvic pain [ICD-11: GA34] |
P10275 | ANDR_HUMAN | Hypo-osmolality/hyponatraemia [ICD-11: 5C72] |
P10275 | ANDR_HUMAN | Low bone mass disorder [ICD-11: FB83] |
P10275 | ANDR_HUMAN | Mammary tumour [ICD-11: 2C60-2C6Z] |
P10275 | ANDR_HUMAN | Pituitary gland disorder [ICD-11: 5A60-5A61] |
P10275 | ANDR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P10275 | ANDR_HUMAN | Testicular dysfunction [ICD-11: 5A81] |
P10275 | ANDR_HUMAN | Prostate hyperplasia [ICD-11: GA90] |
P10275 | ANDR_HUMAN | Alopecia [ICD-11: ED70] |
P10275 | ANDR_HUMAN | Chronic kidney disease [ICD-11: GB61] |
P10275 | ANDR_HUMAN | Thrombosis [ICD-11: DB61-GB90] |
P10275 | ANDR_HUMAN | Contraceptive management [ICD-11: QA21] |
P10275 | ANDR_HUMAN | Heart failure [ICD-11: BD10-BD1Z] |
P10275 | ANDR_HUMAN | Muscle disorder [ICD-11: FB32-FB3Z] |
P10275 | ANDR_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P10275 | ANDR_HUMAN | Cystic fibrosis [ICD-11: CA25] |
P10275 | ANDR_HUMAN | Pain [ICD-11: MG30-MG3Z] |
P10275 | ANDR_HUMAN | Cachexia [ICD-11: MG20] |
P10275 | ANDR_HUMAN | Dissociative neurological symptom disorder [ICD-11: 6B60] |
P10275 | ANDR_HUMAN | Bladder cancer [ICD-11: 2C94] |
P10275 | ANDR_HUMAN | Oesophagitis [ICD-11: DA24] |
P10275 | ANDR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10275 | ANDR_HUMAN | Prostate hyperplasia [ICD-11: GA90] |
P10275 | ANDR_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
P10275 | ANDR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P10275 | ANDR_HUMAN | Acne vulgaris [ICD-11: ED80] |
P10275 | ANDR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16236 | NF2L2_HUMAN | Ataxic disorder [ICD-11: 8A03] |
Q16236 | NF2L2_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 | NF2L2_HUMAN | Glaucoma [ICD-11: 9C61] |
Q16236 | NF2L2_HUMAN | Lung cancer [ICD-11: 2C25] |
Q16236 | NF2L2_HUMAN | Macular degeneration [ICD-11: 9B75] |
Q16236 | NF2L2_HUMAN | Melanoma [ICD-11: 2C30] |
Q16236 | NF2L2_HUMAN | Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 | NF2L2_HUMAN | Pulmonary hypertension [ICD-11: BB01] |
Q16236 | NF2L2_HUMAN | Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 | NF2L2_HUMAN | Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 | NF2L2_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 | NF2L2_HUMAN | Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 | NF2L2_HUMAN | Motor neuron disease [ICD-11: 8B60] |
Q16236 | NF2L2_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P19838 | NFKB1_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P19838 | NFKB1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P19838 | NFKB1_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P08183 | MDR1_HUMAN | Lung cancer [ICD-11: 2C25] |
P08183 | MDR1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08183 | MDR1_HUMAN | Bacterial infection [ICD-11: 1A00-1C4Z] |
P08183 | MDR1_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P08183 | MDR1_HUMAN | Adrenal cancer [ICD-11: 2D11] |
P08183 | MDR1_HUMAN | Ovarian cancer [ICD-11: 2C73] |
P04150 | GCR_HUMAN | Acute diabete complication [ICD-11: 5A2Y] |
P04150 | GCR_HUMAN | Indeterminate colitis [ICD-11: DD72] |
P04150 | GCR_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P04150 | GCR_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P04150 | GCR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P04150 | GCR_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P04150 | GCR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 | GCR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 | GCR_HUMAN | Adaptive immunity immunodeficiency [ICD-11: 4A01] |
P04150 | GCR_HUMAN | Adrenogenital disorder [ICD-11: 5A71] |
P04150 | GCR_HUMAN | Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P04150 | GCR_HUMAN | Asthma [ICD-11: CA23] |
P04150 | GCR_HUMAN | Atopic eczema [ICD-11: EA80] |
P04150 | GCR_HUMAN | Chronic obstructive pulmonary disease [ICD-11: CA22] |
P04150 | GCR_HUMAN | Cushing syndrome [ICD-11: 5A70] |
P04150 | GCR_HUMAN | Eczema [ICD-11: EA80-EA89] |
P04150 | GCR_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P04150 | GCR_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P04150 | GCR_HUMAN | Oesophagitis [ICD-11: DA24] |
P04150 | GCR_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P04150 | GCR_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P04150 | GCR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 | GCR_HUMAN | Spine/trunk injury [ICD-11: ND51] |
P04150 | GCR_HUMAN | Vasomotor/allergic rhinitis [ICD-11: CA08] |
P04150 | GCR_HUMAN | Herpes simplex infection [ICD-11: 1F00] |
P04150 | GCR_HUMAN | Otitis externa [ICD-11: AA00-AA13] |
P04150 | GCR_HUMAN | Substance abuse [ICD-11: 6C40] |
P04150 | GCR_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
P04150 | GCR_HUMAN | Depression [ICD-11: 6A70-6A7Z] |
P04150 | GCR_HUMAN | Mood disorder [ICD-11: 6A60-6E23] |
P04150 | GCR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 | GCR_HUMAN | Vitamin deficiency [ICD-11: 5B55-5B5F] |
P04150 | GCR_HUMAN | Retinopathy [ICD-11: 9B71] |
P04150 | GCR_HUMAN | Anxiety disorder [ICD-11: 6B00-6B0Z] |
P04150 | GCR_HUMAN | Acute diabete complication [ICD-11: 5A2Y] |
P04150 | GCR_HUMAN | Indeterminate colitis [ICD-11: DD72] |
P04150 | GCR_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P04150 | GCR_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P04150 | GCR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P04150 | GCR_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P04150 | GCR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 | GCR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 | GCR_HUMAN | Adaptive immunity immunodeficiency [ICD-11: 4A01] |
P04150 | GCR_HUMAN | Adrenogenital disorder [ICD-11: 5A71] |
P04150 | GCR_HUMAN | Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P04150 | GCR_HUMAN | Asthma [ICD-11: CA23] |
P04150 | GCR_HUMAN | Atopic eczema [ICD-11: EA80] |
P04150 | GCR_HUMAN | Chronic obstructive pulmonary disease [ICD-11: CA22] |
P04150 | GCR_HUMAN | Cushing syndrome [ICD-11: 5A70] |
P04150 | GCR_HUMAN | Eczema [ICD-11: EA80-EA89] |
P04150 | GCR_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P04150 | GCR_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P04150 | GCR_HUMAN | Oesophagitis [ICD-11: DA24] |
P04150 | GCR_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P04150 | GCR_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P04150 | GCR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 | GCR_HUMAN | Spine/trunk injury [ICD-11: ND51] |
P04150 | GCR_HUMAN | Vasomotor/allergic rhinitis [ICD-11: CA08] |
P04150 | GCR_HUMAN | Herpes simplex infection [ICD-11: 1F00] |
P04150 | GCR_HUMAN | Otitis externa [ICD-11: AA00-AA13] |
P04150 | GCR_HUMAN | Substance abuse [ICD-11: 6C40] |
P04150 | GCR_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
P04150 | GCR_HUMAN | Depression [ICD-11: 6A70-6A7Z] |
P04150 | GCR_HUMAN | Mood disorder [ICD-11: 6A60-6E23] |
P04150 | GCR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 | GCR_HUMAN | Vitamin deficiency [ICD-11: 5B55-5B5F] |
P04150 | GCR_HUMAN | Retinopathy [ICD-11: 9B71] |
P04150 | GCR_HUMAN | Anxiety disorder [ICD-11: 6B00-6B0Z] |
P25779 | CYSP_TRYCR | Parasitic worm infestation [ICD-11: 1F90] |
P25779 | CYSP_TRYCR | Malaria [ICD-11: 1F40-1F45] |
Q16665 | HIF1A_HUMAN | Adrenomedullary hyperfunction [ICD-11: 5A75] |
Q16665 | HIF1A_HUMAN | Brain cancer [ICD-11: 2A00] |
Q16665 | HIF1A_HUMAN | Lymphoma [ICD-11: 2A80-2A86] |
Q16665 | HIF1A_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16665 | HIF1A_HUMAN | Pulmonary hypertension [ICD-11: BB01] |
P19793 | RXRA_HUMAN | Kaposi sarcoma [ICD-11: 2B57] |
P19793 | RXRA_HUMAN | Mycosis fungoides [ICD-11: 2B01] |
P08235 | MCR_HUMAN | Adrenocortical insufficiency [ICD-11: 5A74] |
P08235 | MCR_HUMAN | Contraceptive management [ICD-11: QA21] |
P08235 | MCR_HUMAN | Heart failure [ICD-11: BD10-BD1Z] |
P08235 | MCR_HUMAN | Hypertension [ICD-11: BA00-BA04] |
P08235 | MCR_HUMAN | Hypo-osmolality/hyponatraemia [ICD-11: 5C72] |
P08235 | MCR_HUMAN | Chronic kidney disease [ICD-11: GB61] |
P08235 | MCR_HUMAN | Cardiovascular disease [ICD-11: BA00-BE2Z] |
P08235 | MCR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P08235 | MCR_HUMAN | Human immunodeficiency virus disease [ICD-11: 1C60-1C62] |
P08235 | MCR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08235 | MCR_HUMAN | Adrenocortical insufficiency [ICD-11: 5A74] |
P08235 | MCR_HUMAN | Contraceptive management [ICD-11: QA21] |
P08235 | MCR_HUMAN | Heart failure [ICD-11: BD10-BD1Z] |
P08235 | MCR_HUMAN | Hypertension [ICD-11: BA00-BA04] |
P08235 | MCR_HUMAN | Hypo-osmolality/hyponatraemia [ICD-11: 5C72] |
P08235 | MCR_HUMAN | Chronic kidney disease [ICD-11: GB61] |
P08235 | MCR_HUMAN | Cardiovascular disease [ICD-11: BA00-BE2Z] |
P08235 | MCR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P08235 | MCR_HUMAN | Human immunodeficiency virus disease [ICD-11: 1C60-1C62] |
P08235 | MCR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08185 | CBG_HUMAN | Asthma [ICD-11: CA23] |
P08185 | CBG_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P08185 | CBG_HUMAN | Respiratory system disease [ICD-11: CB40-CB7Z] |
P08185 | CBG_HUMAN | Retinopathy [ICD-11: 9B71] |
Q9UNQ0 | ABCG2_HUMAN | Irritable bowel syndrome [ICD-11: DD91] |
Q9UNQ0 | ABCG2_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |